Poorly Differentiated Squamous Cell Carcinoma of Unknown Primary
For poorly differentiated squamous cell carcinoma of unknown primary involving cervical lymph nodes, treat as head and neck squamous cell carcinoma with neck dissection and/or bilateral neck and head-neck axis radiotherapy, with platinum-based chemotherapy or chemoradiation for advanced stages 1.
Staging Work-Up
The diagnostic evaluation must aggressively pursue identification of the primary tumor, as this is a favorable subset of cancer of unknown primary (CUP) when involving non-supraclavicular cervical nodes 1, 2.
Essential Imaging and Endoscopy
- FDG-PET scan is mandatory to direct specific mucosal biopsy and identify the occult primary 3
- Contrast-enhanced CT and/or MRI of head and neck to assess regional lymph nodes and potential primary sites 3
- Chest CT to exclude distant metastases and second primary lung cancer 3
- Flexible head and neck fiberoptic endoscopy with examination under general anesthesia 3
- Panendoscopy with biopsies of nasopharynx, hypopharynx, and oropharynx, including bilateral tonsillectomy if primary remains elusive 2
Critical Pathological Testing
- p16 immunohistochemistry is mandatory for all neck metastases of unknown origin 3, 2
- EBV status by EBER in situ hybridization to exclude nasopharyngeal cancer 3, 2
- PD-L1 expression should be assessed if recurrent or metastatic disease develops 3
Common Pitfall: Do not assume p16-positive equals HPV-positive—10-15% are false positives requiring confirmatory HPV testing 3.
First-Line Treatment
Treatment depends on disease extent and should mirror head and neck squamous cell carcinoma protocols 1, 2.
Localized Disease (Non-Supraclavicular Cervical Nodes)
For small-volume neck disease:
- Either neck dissection OR chemoradiotherapy 2
- Neck dissection alone may be considered for highly selected early-stage cases 5
For large-volume disease:
- Combination of neck dissection AND chemoradiotherapy 2
Radiation Field
- Bilateral neck and entire head-neck mucosal axis should be irradiated 1
- This comprehensive field approach reduces primary tumor emergence (only 11% vs 21.6% with limited fields) 6
Advanced Stage Disease
- Induction chemotherapy with platinum-based combination (docetaxel/cisplatin/5-FU or paclitaxel/cisplatin/5-FU) followed by chemoradiation 1
- These three-drug regimens produce superior response rates (80% vs 59% for two-drug regimens) 7
Important Caveat: The evidence strongly supports treating squamous cell carcinoma involving cervical lymph nodes as head and neck cancer rather than as generic CUP, as this subset has significantly better prognosis and treatment responsiveness 1, 2.
Prognostic Factors
N-stage and extracapsular spread are the two major independent prognostic factors affecting survival 6. HPV-positive status confers better prognosis, though treatment de-escalation is not currently recommended outside clinical trials 4.
Metastatic or Unresectable Disease
- Anti-PD-1 agents (cemiplimab) as first-line systemic therapy for patients not candidates for curative surgery or radiotherapy 2
- Second-line options include EGFR inhibitors (cetuximab) combined with anti-PD-1, or traditional chemotherapy 2
Follow-Up
Monitor at least 5 years with decreasing frequency: 4 times yearly for years 1-2,3 times yearly for year 3, then twice yearly through year 5 8. Watch for primary tumor emergence, which occurs in 21-27% of cases (median 15 months post-treatment) 6.